Clinical Trial Update: Fenretinide in Treating Patients With Recurrent Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update of fenretinide for recurrent small cell lung cancer; the National Cancer Institute–sponsored study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Fenretinide (fenretinide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED